A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal patch delivering 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol…
AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly improved disease-free survival (DFS) for patients with high-risk non-muscle-invasive…
Shionogi Forms Comprehensive Partnership to Strengthen Antimicrobial Stewardship in Kenya Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka; “Shionogi”) is pleased to announce that it has signed a comprehensive partnership agreement with Nagasaki University (Nagasaki City, Nagasaki), Saraya Co., Ltd.…
GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor, in adults…
Eli Lilly Announces Executive Leadership Changes to Propel Future Growth Eli Lilly and Company (NYSE: LLY) today announced a series of executive leadership transitions designed to strengthen its ability to deliver sustained, long-term growth and expand access to its medicines…
Otsuka Pharmaceutical Signs Research Agreement with Keio University to Advance Psychedelic Treatment Infrastructure in Japan Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that it has signed a non-clinical (basic research) agreement with Keio University (Keio) to collaborate on developing the…
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving the lives of people with severe autoimmune diseases, today announced its financial results for the first quarter of 2025 and provided a comprehensive business update. CEO Statement…
Strong FY2024 Performance and Strategic Outlook for FY2025 The company reported core revenue growth of 7.4% at actual exchange rates (AER) and 2.8% at constant exchange rates (CER) for fiscal year 2024, reflecting solid product performance across key markets. Core…
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment of primary biliary cholangitis (PBC) and also provides sustained biochemical…
Novo Nordisk Reports Strong Operating Profit and Sales Growth, Updates 2025 Outlook Novo Nordisk announced a 22% increase in operating profit in Danish kroner, or 20% growth at constant exchange rates (CER), reaching DKK 38.8 billion. Sales in the US…
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced the launch of its Elecsys® PRO-C3 test, a new diagnostic tool developed in collaboration with Nordic Bioscience, to assess the severity of liver fibrosis in patients with metabolic dysfunction–associated steatotic liver disease…
GSK to Present 43 Abstracts Across Respiratory Portfolio at ATS 2025, Including New Data on Mepolizumab and Depemokimab GSK plc (LSE/NYSE: GSK) today announced that 43 abstracts, including four late-breaking submissions, from its inhaled and respiratory biologics portfolio will be…